Prescription Weight Loss Programme (GLP-1)

Medically supervised weight management using a once-weekly GLP-1 receptor agonist injection (semaglutide analogue), with dose escalation from week 1 through to a 2.4 mg maintenance dose, combined with dietary and activity guidance.

DTAP Clinic's prescription weight loss programme centres on the GLP-1 receptor agonist class of injectable medications — the same active mechanism as Ozempic and Wegovy (semaglutide). The programme is physician-led, beginning with a BMI and medical history assessment to confirm eligibility and screen for contraindications including personal or family history of thyroid cancer, pancreatitis, or severe gastrointestinal disease. Eligible patients start on a low weekly dose to establish tolerability and reduce side effects such as nausea and fatigue, then progress through a dose-escalation schedule over 16 weeks to the maintenance dose of 1.7 mg or 2.4 mg weekly. Clinical studies using semaglutide 2.4 mg demonstrated average weight loss of approximately 15% of total body weight over 68 weeks, with a proportion of participants achieving 20% or more. DTAP doctors pair the injectable with practical behavioural guidance on caloric reduction and physical activity, and schedule follow-up appointments to monitor weight trajectory, metabolic markers, heart rate, and any adverse effects. The programme is distinct from online-only GLP-1 prescribing services in that it offers in-person clinic visits at seven Singapore locations, enabling blood pressure monitoring, repeat metabolic blood panels, and rapid escalation or de-escalation of dosing based on clinical response. This is an appropriate option for adults with a BMI of 27 or above with weight-related comorbidities, or BMI of 30 or above regardless of comorbidities.